Envista Holdings stock hits 52-week low at $15.14

Envista Holdings Corp (NYSE:NVST) stock has touched a 52-week low, dipping to $15.14, signaling a period of bearish momentum for the company’s shares. According to InvestingPro data, the company maintains a healthy financial position with a "GOOD" overall score and strong free cash flow yield of ~11%. This latest price level reflects a significant retreat from more favorable valuations over the past year, with the stock experiencing a 1-year change that shows a notable decline of 25.9%. Investors are closely monitoring Envista Holdings as it navigates through market challenges that have pushed its valuation to the lower end of its 52-week spectrum. The company’s performance and future outlook remain under scrutiny, though analyst targets suggest potential upside, with price targets ranging from $18 to $26. InvestingPro analysis indicates the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.

In other recent news, Envista Holdings Corp. reported fourth-quarter financial results that exceeded consensus expectations for both revenue and earnings, showcasing strong performance in its dental implants segment. However, the company’s guidance for 2025 did not meet analyst predictions, leading Needham analysts to maintain a Hold rating on the stock. Meanwhile, Stifel analysts reiterated their Buy rating with a $24 price target, highlighting the company’s strategic focus on its Specialty Products & Technologies division. Mizuho (NYSE:MFG) Securities adjusted their price target for Envista to $18, maintaining an Underperform rating due to projections falling short of consensus forecasts for EBITDA and EPS growth in the coming years. JPMorgan also revised their price target to $19, keeping a Neutral rating, while noting the company’s confidence in its medium-term targets despite external challenges. Envista’s Capital Markets Day is anticipated to provide further insights into its long-term strategies, particularly in orthodontics and implants. The company’s new management team has expressed a commitment to regaining investor trust through achievable guidance and a focus on innovation. Investors are keenly awaiting more detailed information on Envista’s strategic plans and financial goals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.